Bloomberg Law
June 18, 2020, 8:07 PM

Mylan Wins Court Decision Against Biogen’s Tecfidera Patent

Linly Lin
Linly Lin
Bloomberg News

Mylan says U.S. District Court for the Northern District of West Virginia invalidated Biogen’s Tecfidera patent for lack of written description.

  • The ᾿514 patent claimed methods of treating multiple sclerosis (MS) using a dose of 480 mg/day of dimethyl fumarate delayed release capsules
  • Decision clears the way for Mylan’s launch of its dimethyl fumarate product upon the receipt of FDA approval
  • The ‘514 patent could have otherwise delayed generic competition until 2028
  • Biogen’s total IQVIA sales in the U.S. for the 12 months ending April 30, 2020, were approximately $3.78 billion for Tecfidera

To view the source of this information ...